In the present study, a series of 2,3-dihydro-1,5-benzothiazepine
derivatives
1B
–
14B
has been synthesized
sand characterized by various spectroscopic techniques. The enzyme
inhibitory activities of the target analogues were assessed using
in vitro
and
in vivo
mechanism-based assays.
The tested compounds
1B
–
14B
exhibited
in vitro
inhibitory potential against α-glucosidase
with IC
50
= 2.62 ± 0.16 to 10.11 ± 0.32 μM
as compared to the standard drug acarbose (IC
50
= 37.38
± 1.37 μM). Kinetic studies of the most active derivatives
2B
and
3B
illustrated competitive inhibitions.
Based on the α-glucosidase inhibitory effect, the compounds
2B
,
3B
,
6B
,
7B
,
12B
,
13B
, and
14B
were chosen
in vivo
for further evaluation of antidiabetic activity
in streptozotocin-induced diabetic Wistar rats. All these evaluated
compounds demonstrated significant antidiabetic activity and were
found to be nontoxic in nature. Moreover, the molecular docking study
was performed to elucidate the binding interactions of most active
analogues with the various sites of the α-glucosidase enzyme
(PDB ID
3AJ7
). Additionally, quantitative structure–activity relationship
(QSAR) studies were performed based on the α-glucosidase inhibitory
assay. The value of correlation coefficient (
r
) 0.9553
shows that there was a good correlation between the
1B
–
14B
structures and selected properties. There
is a correlation between the experimental and theoretical results.
Thus, these novel compounds could serve as potential candidates to
become leads for the development of new drugs provoking an anti-hyperglycemic
effect.